The Filing Desk

Tilray Brands vs Telix Pharmaceuticals

Tilray Brands TLRY · Telix Pharmaceuticals TLX · Pharmaceuticals

Tilray Brands reported revenue of $916 million in fiscal 2026, about the same as Telix Pharmaceuticals' $804 million in fiscal 2025. Tilray Brands' revenue grew 11.5% in its latest year, and Telix Pharmaceuticals' grew 55.6%. Tilray Brands had an operating margin of -6.9%, against 3.7% at Telix Pharmaceuticals. Their fiscal years end in different months (May 31 and December 31), so the periods don't line up exactly.

Side by side

Tilray BrandsTelix Pharmaceuticals
Latest fiscal yearFY2026, May 31, 2026FY2025, Dec 31, 2025
Revenue$916M$804M
Revenue growth11.5%55.6%
Revenue growth a year, last 5 years12.3%—
Gross margin28.4%53.0%
Operating margin−6.9%3.7%
Net margin−13.3%−0.9%
Free cash flow—−$43M
Free cash flow margin—−5.3%
Return on capital−3.4%5.0%
Net debt to EBITDA—5.1x
Dividends and buybacks$0M$0M
Change in diluted share count25.6%−2.1%
Last close$2.07$8.71
P/E at the last close——
Insider trades, last 12 monthsbought $69,225, sold $232,879bought $1.0 million, sold $0
Piotroski F-score3 of 92 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Tilray BrandsTelix Pharmaceuticals
Operating margin
Percent of revenue
Tilray BrandsTelix Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Tilray BrandsTelix Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Tilray Brands and Telix Pharmaceuticals pages.